Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
etherna logo — Enabling Nucleic Acid Medicines for Next‑Generation Therapie...

etherna

Enabling Nucleic Acid Medicines for Next‑Generation Therapies | www.etherna.be

Founded 2013 Belgium Belgium 91 employees Series B Total: $104.90M Biotechnology, Health Care +2

General Information

Company Name etherna
Founded Year 2013
Location Belgium Belgium +2
Founders / Decision Makers
Team member
Employees 91
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Series B
Social

Get notified when etherna moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About etherna

etherna, founded in 2013, is a pioneering company in the domain of nucleic acid–based medicine technology, headquartered in Belgium. The company operates a platform that addresses the intricate challenges of RNA chemistry and LNP formulation, effectively supporting both emerging and established players in the pharma and biotech industries.

The expertise of etherna in driving discovery and resolving manufacturing complications positions it as an essential partner for biotech firms developing next-generation therapies. This strategic alignment is underscored by their slogan, "Enabling Nucleic Acid Medicines for Next‑Generation Therapies."

In recent times, etherna secured a substantial €39.00M Series B investment on 01 August 2022, supported by notable investors such as Kennet Partners, FunPlus Ventures, Novalis LifeSciences, Omega Funds, PMV, and China Grand Pharmaceutical and Healthcare Holdings, along with EQT Life Sciences. This financial backing reflects strong confidence in their capacity to advance pivotal healthcare solutions.

Taxonomy: Nucleic Acid Medicines, RNA Chemistry, LNP Formulation, Nucleic Acid Therapeutics, mRNA Production, Drug Product Production, Process Technologies, GMP mRNA, mRNA Therapies, Biotech Partnerships, Pharma Collaborations, Pipeline Development, Manufacturing Solutions, Technology Platform, Nucleic Acid-Based Drug Development

Services & Products

LNP platforms development
mRNA platforms development
RNA chemistry expertise
Technology partnering
Product partnering
Pipeline development
Manufacturing solutions

Target Customers

Pharmaceutical companies Biotech companies Start-up projects Early-stage projects Late-stage projects

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 7
Investor Investor Investor Investor Investor Investor
•••• •••• 		01 Aug 2022
Grant •••••• 1 •••• •••• 01 Mar 2021
Series B •••••• 8
Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		01 Jun 2020
Grant •••••• 2
Investor
•••• •••• 		01 Sep 2017
Series A •••••• 3
Investor
•••• •••• 		01 Mar 2016

View All 6 Funding Rounds

etherna Alternatives & Competitors

View All Alternatives
etherna vs
Orion Therapeutics, Inc.
Orion Therapeutics, Inc. United States

Platform technology providing targeted delivery of RNA aimed at curing and preventing previously und...

7 employees
Biotechnology, Health Care
etherna vs
PURMX Therapeutics,Inc.
PURMX Therapeutics,Inc. Japan

Information service targetting pharma and bio.

Series A
9 employees
Biopharma, Biotechnology
Compare etherna vs PURMX Therapeutics,Inc.
etherna vs
NanoVation Therapeutics™
NanoVation Therapeutics™ Canada

Delivering tomorrow's genetic medicines, today™

Grant
42 employees
Biotechnology, Health and Wellness
Compare etherna vs NanoVation Therapeutics™
Also compare with: etherna vs Arcturus Therapeutics Arcturus Therapeutics View all alternatives

FAQ About etherna

Enabling Nucleic Acid Medicines for Next‑Generation Therapies | www.etherna.be
etherna was founded in 2013.
etherna is headquartered in Belgium.
etherna operates in the following industries: Biotechnology, Health Care, Health and Wellness, Medical Devices.
etherna has approximately 91 employees.
etherna has completed 6 funding rounds, raising a total of $104.90M. The latest funding stage is Series B.
etherna offers: LNP platforms development, mRNA platforms development, RNA chemistry expertise, Technology partnering, Product partnering, Pipeline development, Manufacturing solutions.
Top alternatives and competitors to etherna include Orion Therapeutics, Inc., PURMX Therapeutics,Inc., NanoVation Therapeutics™, Arcturus Therapeutics, Axolabs. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
etherna and Orion Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors etherna and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy